- HIPAA-compliant billing • BAA with every client
- Serving practices in all 50 states
ONCOLOGY BILLING • CHEMOTHERAPY & INFUSION CLAIMS • DRUG REIMBURSEMENT
We help cancer practices code chemo & infusion time correctly convert doses to HCPCS drug units match authorizations to the regimen apply JW & JZ with documentation recover denied drug claims
The Treatment Was Delivered. Has the Revenue Been Accounted For?
Cancer treatment involves expensive medications, repeat infusion visits, changing treatment plans and detailed payer rules. SkyLine MB provides oncology billing services that manage the billing process behind that care.
LET'S TALK
Get a Free Oncology Billing Review
Tell us about your cancer practice and the treatment claims you’d like reviewed.
Please do not include patient names, diagnoses or protected health information.
TREATMENT-TO-CLAIM
96413 • 96415 • J-codes • JW/JZ
Infusion time, drug units and approval reconciled.
ONCOLOGY BILLING, EXPLAINED
Oncology medical billing services manage insurance claims and reimbursement for cancer-related consultations, chemotherapy, immunotherapy, eligible infusion therapies, injectable medications and associated treatment services.
What makes oncology different is the close link between clinical treatment and medication reimbursement. One infusion visit may need benefit verification, approval for a specific drug, documented quantities, administration coding and separate drug reporting with HCPCS units — and requirements change when a regimen or payer policy changes.
SkyLine MB connects treatment documentation, authorization information, charge entry, insurance claims and reimbursement follow-up.
Reviewed by the SkyLine MB billing & coding team · Last updated October 2026
Behind every treatment is a detailed claim
Linking administration records, approved therapy, accurate charges and insurance reimbursement.
MEDICAL ONCOLOGY REVENUE SUPPORT
When a patient arrives for chemotherapy, the practice may already have purchased the drug. After it is prepared, administered and documented, billing must decide which administration services are reportable, which drug code applies, how many HCPCS units match the dose, and whether discarded quantity needs reporting.
One discrepancy can delay payment for an expensive treatment; another can cause underpayment — and the risk multiplies across drugs, cycles, physicians and plans.
SkyLine MB helps cancer centers review the information behind those claims. With 10 years of medical billing experience, we handle documentation checks, claim preparation, denials, payment posting and A/R — with extra attention to how buy-and-bill treatment becomes reimbursable drug charges.
Cancer care is complex enough. Your billing process should bring clarity, not more uncertainty.
SPECIALTY REVENUE CYCLE SERVICES
Nine connected services for chemotherapy, infusion and drug claims.
01
Treatment plans involve repeat visits and changing insurance details.
We review coverage, specialty drug benefits, copays, deductibles and payer requirements.
02
Approval may depend on drug, diagnosis, dose, cycle and location.
We monitor authorization details and flag discrepancies before affected claims go out.
03
We reconcile documented treatment against the claim.
Administration CPT codes, drug HCPCS units and modifiers are reviewed — see the oncology code table.
04
Submit supported medical oncology claims.
We include accurate patient, provider, diagnosis, procedure, medication and payer data, and review rejections.
05
Get to the cause of a drug or administration denial.
We work authorization, necessity, drug coding and unit denials, with corrections or appeals where supported.
06
Unpaid treatment claims can include costly purchased drugs.
We organize aging balances and prioritize claims needing payer attention.
07
We post payments, adjustments and balances from remittances.
With payer agreements and drug data, we investigate reimbursement discrepancies.
08
Keep oncologists enrolled with the plans you bill.
We assist with credentialing, CAQH, payer enrollment follow-up and record updates.
09
Clear account information for staff and owners.
We organize patient balances, statements, claims, denials and outstanding reimbursement reports.
CHEMOTHERAPY & INFUSION CODING
Drug type, route of administration, infusion duration and service sequence influence the codes that apply.
| CPT code | General service | Key billing consideration |
|---|---|---|
| 96401 | Chemotherapy administration, subcutaneous or IM, specified drugs | Qualifying medication and route |
| 96402 | Chemotherapy administration, SC/IM, hormonal antineoplastic | Drug classification and payer policy |
| 96409 | Chemotherapy administration, IV push, single or initial drug | Actual administration method |
| 96411 | Additional qualifying chemotherapy IV push drug | Sequential drug requirements |
| 96413 | Chemotherapy administration, IV infusion, initial hour | Treatment type and documented time |
| 96415 | Each additional hour of chemotherapy infusion | Timing and add-on rules |
| 96417 | Sequential chemotherapy infusion of another drug, initial hour | Administration sequence and documentation |
| 96365 | Nonchemotherapy therapeutic infusion, initial hour | Infusion category and timing |
| 96366 | Each additional hour of nonchemotherapy infusion | Documented duration and add-on rules |
| 96367 | Sequential infusion of a new nonchemotherapy drug | Sequential administration rules |
| 96372 | Therapeutic, prophylactic or diagnostic injection, SC/IM | Qualifying injection and bundling |
| 99213–99215 | Established-patient office/outpatient E/M | Separately supported MDM or time |
Drug charges: chemotherapy and immunotherapy medications may need separate, product-specific HCPCS codes and exact billing-unit conversions — an administration code doesn’t represent the drug supplied. Descriptions simplified; verify against current CPT/HCPCS definitions, CMS policy and payer rules. CPT® is a registered trademark of the American Medical Association.
2026 ONCOLOGY CODING & REIMBURSEMENT
A medication can be administered correctly and still be billed incorrectly. The revenue cycle has to account for both.
Approval may be tied to the drug, diagnosis, dose, cycle count or site of care.
When the regimen changes, the existing authorization may no longer match the service billed.
Initial (96413), additional hour (96415) and sequential (96417) codes aren’t interchangeable.
Port access and routine flushing may already be included in the primary service.
Doses in milligrams must convert to HCPCS billing units per the code descriptor — never assume 1 mg = 1 unit.
JW/JZ apply to qualifying single-dose drugs; biosimilars and site of care can change payment.
Based on CPT chemotherapy and infusion administration guidelines, HCPCS Level II drug descriptors, CMS JW/JZ discarded-drug policy and payer oncology drug policies.
MEDICATION & CLAIM ACCURACY
Drug modifiers and information must follow the specific product, payer and policy. Neither modifier selection nor drug quantities should rest on assumptions.
| Modifier / claim detail | What it identifies | What needs attention |
|---|---|---|
| JW | Discarded amount from a qualifying single-dose container | Documented wastage and correct units |
| JZ | No discarded amount for a qualifying single-dose drug | Documentation supporting zero wastage |
| 25 | Significant, separately identifiable E/M on a procedure day | Independent E/M work and documentation |
| 59 | Distinct procedural service when permitted | Coding edits and documentation |
| XE | Service in a separate encounter | Genuinely distinct encounter |
| XP | Service by a separate practitioner | Payer and coding-rule applicability |
| XS | Service on a separate structure | Documentation supporting separate reporting |
| NDC information | Drug identification when the payer requires it | Correct product, package and quantity |
| HCPCS drug units | Quantity represented by the drug code | Correct conversion from documented dose |
CANCER CARE PRACTICES WE SUPPORT
We align billing with the treatment services your practice delivers:
Also running neurology infusions? See our neurology billing services.
COMMON ONCOLOGY BILLING CHALLENGES
High-cost drugs make every billing gap expensive.
Authorization mismatch, wrong product code or unsupported units.
Initial, additional and sequential services follow strict rules.
The approved drug or dose differs from what was administered.
Missing or unsupported JW/JZ creates payment and compliance issues.
Medication and administration follow different payment rules.
One unpaid specialty drug claim can be a substantial balance.
TREATMENT-TO-CLAIM RECONCILIATION
Before a claim reaches the insurer, the billing should match what the practice actually administered. We connect three records:
We flag discrepancies that need correction or clinical clarification. When approved therapies, doses or periods change, our prior authorization support coordinates the payer requirements.
Oncology treatment billing tracker
ILLUSTRATIVE
OUR PROCESS
Built around treatment cycles, drug claims and authorizations.
01
We review providers, regimens, payer mix, drug model and open A/R.
02
We confirm how orders, MARs and infusion times reach billing.
03
Administration codes, HCPCS units, JW/JZ and authorizations are checked.
04
Drug and administration payments are reconciled; denials are worked.
05
Monthly reports by drug, treatment category and payer.
WHY SKYLINE MB
Structured revenue cycle support for complex specialty claims.
Administered quantities converted to HCPCS units per descriptor.
Initial, add-on and sequential codes matched to documented time.
Approvals kept aligned with regimen, dose and cycle changes.
Wastage reporting backed by administration records.
Payments and A/R by drug, treatment and payer.
ONCOLOGY BILLING SUPPORT COMPARISON
Outsourcing shouldn’t remove your control over medication records or treatment decisions.
It should establish clear responsibility for turning documented treatment into supported claims and investigating the reimbursements that follow.
| Oncology billing responsibility | In-house team | General billing company | SkyLine MB oncology support |
|---|---|---|---|
| Chemotherapy administration coding | Requires specialty knowledge | May need added expertise | Infusion and injection coding review |
| HCPCS drug billing units | Internal reconciliation | General charge entry | Dose-to-unit reconciliation |
| Drug authorization tracking | Practice staff responsibility | Varies by scope | Treatment authorization review |
| JW/JZ reporting | Requires medication records | Depends on capability | Drug modifier checks |
| High-cost drug denials | Internal payer follow-up | Contract-dependent | Denial investigation and follow-up |
| Medication-related A/R | Requires consistent review | Depends on vendor | Outstanding drug-claim tracking |
PAYERS, COMPLIANCE & SOFTWARE
Coverage can differ by drug, indication, site of care, administration method and authorization. In buy-and-bill the practice purchases the drug and seeks reimbursement; with specialty pharmacy or white-bagging, billing depends on which entity supplied the drug.
Claims are billed only for treatment actually administered and documented; documentation gaps go back to the treating provider. SkyLine MB follows applicable HIPAA requirements, signs a Business Associate Agreement and uses role-based access.
Works inside your EHR & PM system
Concerned about oncology drug billing?
Request a free oncology billing review. We’ll look at infusion coding, drug units, authorizations, JW/JZ and aged A/R.
SPECIALTY FINANCIAL REPORTING
Reporting by drug, treatment category and payer.
Infusions and injections pending documentation or charges.
Medication claims needing investigation.
Authorization, necessity, coding, administration and enrollment.
Balances by payer, drug, service and aging period.
Collected vs. collectible under payer arrangements.
Visits, chemotherapy, immunotherapy, infusions and injections.
ONCOLOGY BILLING FAQS
Oncology billing services manage insurance claims and reimbursement for cancer consultations, chemotherapy, immunotherapy, infusion administration, injectable medications and related covered treatment. They can include eligibility checks, authorizations, coding review, claim submission, payment posting, denials and A/R follow-up.
Oncology practices may purchase costly medications, administer treatments over documented time periods and bill both administration procedures and separately reportable drugs. Payer authorizations, HCPCS billing units and medication coverage requirements add complexity.
Common codes include 96413 for the initial hour of qualifying chemotherapy IV infusion, 96415 for each additional hour and 96417 for an eligible sequential chemotherapy infusion. Actual coding depends on the documented service and current CPT guidance.
Chemotherapy administration and nonchemotherapy therapeutic infusion use different code families and rules. Classification depends on the medication, administration and coding guidance rather than the diagnosis alone.
J-codes are HCPCS Level II codes used for certain drugs and biologicals. Each code identifies a product or category and defines the quantity represented by one billing unit. Not all oncology medications use J-codes.
The documented quantity administered is converted into billing units using the specific HCPCS drug-code definition. The conversion varies by medication and should not be assumed to be one unit per milligram.
JW identifies an eligible discarded amount of a drug from an applicable single-dose container. Medicare requires supporting documentation and accurate unit reporting under its discarded-drug policy.
JZ indicates that no amount was discarded from an applicable single-dose drug container when the Medicare reporting requirement applies. It is not a substitute for missing medication documentation.
Many payers require prior authorization for particular cancer treatments or drugs. Approval may depend on diagnosis, medication, dose, regimen, site of care and treatment duration.
Yes. We support medication-related denials, including authorization discrepancies, HCPCS coding issues, drug-unit problems, payment follow-up and appropriate corrections or appeals.
Yes. We support hematology-oncology clinics with consultations, eligible infusion and injection services, drug claims and outstanding insurance balances.
Yes. We review your current systems, treatment and billing records, access requirements and compatibility during consultation.
Pricing depends on your providers, treatment volume, drug claim complexity, payer mix and the scope of revenue cycle services. Contact SkyLine MB for a free consultation and a practice-specific proposal.
RELATED SERVICES
Drug and regimen approvals.
Infusion codes and drug units.
Specialty drug benefits.
Drug and administration denials.
High-value claims followed up.
Drug payment reconciliation.
Related specialties:
GET STARTED
Every oncology treatment involves clinical decisions, medication management, patient monitoring and documentation. The insurance process behind that treatment deserves a coordinated approach too.
Whether you run a community oncology clinic, a hematology-oncology group or an independent infusion center, SkyLine MB can discuss the financial workflows that need attention.
Let your clinical team concentrate on treatment. Give your oncology claims the review and follow-up they require.
